Vaxart to Present Norovirus Data at IDWeek 2024 Underscoring Commitment to Address Significant Unmet Need

Rhea-AI Summary

Vaxart (Nasdaq: VXRT) will present research on its norovirus oral pill vaccine candidate at IDWeek 2024 in Los Angeles. With no approved vaccines for norovirus, Vaxart's candidate is the most advanced in clinical development for oral administration and gastrointestinal delivery. Norovirus affects 21 million Americans annually, including 15% of children under 5, forcing 3 million parents to miss work. Adults ≥65 are at high risk for severe symptoms.

Two presentations are scheduled:

• A Phase 2 study on the oral tableted norovirus vaccine VXA-G1.1-NN, showing immunogenicity, efficacy, and reduced viral shedding.
• A Phase I study on the safety, tolerability, and immunogenicity of an orally administered bivalent GI.1/GII.4 norovirus vaccine in lactating females and their infants.

The annual disease burden from norovirus in the US is estimated at $10.6 billion.

SOUTH SAN FRANCISCO, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it will present research demonstrating the potential of its norovirus oral pill vaccine candidate at IDWeek taking place October 16-19, 2024, at the Los Angeles Convention Center in Los Angeles.

With no currently approved vaccines against norovirus, Vaxart remains committed to progressing what it believes to be the most advanced norovirus vaccine candidate in clinical development that is both formulated for oral administration and designed for delivery to the gastrointestinal system. Norovirus sickens approximately 21 million people in the United States each year, including the 15% of children under age 5 who contract norovirus annually. Approximately 3 million sets of parents are forced by this virus to miss work – approximately 2.2 days on average – to care for their children. Adults ≥65 years old are at high-risk for severe symptoms and clinical outcomes including longer disease duration and death. The annual disease burden from norovirus in the United States is estimated to be $10.6 billion

Presentation Information:

Title: A Phase 2 Double-Blind, Placebo-Controlled Study Showing Oral Tableted Norovirus Vaccine VXA-G1.1-NN is Immunogenic, Efficacious, and Reduces Viral Shedding Following Norovirus Challenge
Speaker: Dr. Sean Tucker, Founder and Chief Scientific Officer of Vaxart
Date: Thursday, October 17
Time: 3:45 p.m. PT
Room: 404 AB

Title: A Phase I, Multicenter, Randomized, Double-blind, Placebo-controlled Single Dose, Dose-ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of Orally Administered Bivalent GI.1/GII.4 Norovirus Vaccine in Healthy Lactating Females ≥ 18 years Old and Their Breast-feeding Infants
Speaker: Dr. Lam Nguyen, Medical Director & Head of Pharmacovigilance of Vaxart
Date: Saturday, October 19, 2024
Time: 2:15 p.m. PT
Room: 403 B

About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and to eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Contact

Vaxart Media and Investor Relations
Matt Steinberg
FINN Partners
IR@vaxart.com
(646) 871-8481

This press release was published by a CLEAR® Verified individual.

FAQ

What is Vaxart presenting at IDWeek 2024 regarding their norovirus vaccine candidate?

Vaxart is presenting research on their norovirus oral pill vaccine candidate, including a Phase 2 study showing immunogenicity, efficacy, and reduced viral shedding, and a Phase I study on safety and immunogenicity in lactating females and their infants.

How many people in the United States are affected by norovirus annually according to Vaxart's press release?

According to Vaxart's press release, norovirus affects approximately 21 million people in the United States each year, including 15% of children under age 5.

What is the estimated annual disease burden from norovirus in the United States?

The annual disease burden from norovirus in the United States is estimated to be $10.6 billion, according to the information provided in Vaxart's press release.

When and where is IDWeek 2024 taking place, as mentioned in Vaxart's announcement?

IDWeek 2024 is taking place from October 16-19, 2024, at the Los Angeles Convention Center in Los Angeles, as stated in Vaxart's press release.

What makes Vaxart's norovirus vaccine candidate unique according to the press release?

Vaxart's norovirus vaccine candidate is described as the most advanced in clinical development that is both formulated for oral administration and designed for delivery to the gastrointestinal system.